Cleveland, OH, United States of America

Griffin Beyer

This inventor holds 1 USPTO granted patent. Top assignee: Oakwood Laboratories LLC. Active years: 2024.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Griffin Beyer in Extended-Release Microsphere Formulations

Introduction

Griffin Beyer is an accomplished inventor based in Cleveland, OH. He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of extended-release microsphere formulations. His innovative work focuses on improving the delivery of lurasidone, a medication used in the treatment of certain mental health conditions.

Latest Patents

Griffin Beyer holds a patent for "Microsphere formulations comprising lurasidone and methods for making and using the same." This patent describes extended-release microsphere formulations that allow for the controlled release of lurasidone in vivo over a period of about 30 days. The methods outlined in the patent provide a novel approach to making and utilizing these formulations, enhancing the therapeutic efficacy of the medication.

Career Highlights

Griffin Beyer is associated with Oakwood Laboratories LLC, where he applies his expertise in pharmaceutical development. His work at the company has been instrumental in advancing innovative drug delivery systems that improve patient outcomes.

Collaborations

Griffin collaborates with talented professionals such as Colin Spencer and Tracy Richey. Their combined efforts contribute to the ongoing research and development of effective pharmaceutical solutions.

Conclusion

Griffin Beyer's contributions to the field of pharmaceutical formulations, particularly through his patent on extended-release microsphere formulations, highlight his innovative spirit and dedication to improving healthcare solutions. His work continues to pave the way for advancements in drug delivery systems.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…